Display options
Cite
Phanthong S, Densumite J, Seesuay W, et al. Human Antibodies to VP4 Inhibit Replication of Enteroviruses Across Subgenotypes and Serotypes, and Enhance Host Innate Immunity. Front Microbiol. 2020;11:562768doi: 10.3389/fmicb.2020.562768.
Phanthong, S., Densumite, J., Seesuay, W., Thanongsaksrikul, J., Teimoori, S., Sookrung, N., Poovorawan, Y., Onvimala, N., Guntapong, R., Pattanapanyasat, K., & Chaicumpa, W. (2020). Human Antibodies to VP4 Inhibit Replication of Enteroviruses Across Subgenotypes and Serotypes, and Enhance Host Innate Immunity. Frontiers in microbiology, 11562768. https://doi.org/10.3389/fmicb.2020.562768
Phanthong, Siratcha, et al. "Human Antibodies to VP4 Inhibit Replication of Enteroviruses Across Subgenotypes and Serotypes, and Enhance Host Innate Immunity." Frontiers in microbiology vol. 11 (2020): 562768. doi: https://doi.org/10.3389/fmicb.2020.562768
Phanthong S, Densumite J, Seesuay W, Thanongsaksrikul J, Teimoori S, Sookrung N, Poovorawan Y, Onvimala N, Guntapong R, Pattanapanyasat K, Chaicumpa W. Human Antibodies to VP4 Inhibit Replication of Enteroviruses Across Subgenotypes and Serotypes, and Enhance Host Innate Immunity. Front Microbiol. 2020 Sep 25;11:562768. doi: 10.3389/fmicb.2020.562768. eCollection 2020. PMID: 33101238; PMCID: PMC7545151.
Copy Download .nbib Format: NLM
Share it on

Front Microbiol. 2020 Sep 25;11:562768. doi: 10.3389/fmicb.2020.562768. eCollection 2020.

Human Antibodies to VP4 Inhibit Replication of Enteroviruses Across Subgenotypes and Serotypes, and Enhance Host Innate Immunity.

Frontiers in microbiology

Siratcha Phanthong, Jaslan Densumite, Watee Seesuay, Jeeraphong Thanongsaksrikul, Salma Teimoori, Nitat Sookrung, Yong Poovorawan, Napa Onvimala, Ratigorn Guntapong, Kovit Pattanapanyasat, Wanpen Chaicumpa

Affiliations

  1. Graduate Program in Immunology, Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  2. Department of Parasitology, Faculty of Medicine Siriraj Hospital, Center of Research Excellence in Therapeutic Proteins and Antibody Engineering, Mahidol University, Bangkok, Thailand.
  3. Graduate Program in Biomedical Science, Faculty of Allied Health Sciences, Thammasat University, Bangkok, Thailand.
  4. Biomedical Research Incubator Unit, Department of Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  5. Department of Pediatrics, Faculty of Medicine, Center of Excellence in Clinical Virology, Chulalongkorn University, Bangkok, Thailand.
  6. Department of Medical Science, Ministry of Public Health, National Institute of Health, Nonthaburi, Thailand.

PMID: 33101238 PMCID: PMC7545151 DOI: 10.3389/fmicb.2020.562768

Abstract

Hand, foot, and mouth disease (HFMD) is a highly contagious disease that usually affects infants and young children (<5 years). HFMD outbreaks occur frequently in the Asia-Pacific region, and these outbreaks are associated with enormous healthcare and socioeconomic burden. There is currently no specific antiviral agent to treat HFMD and/or the severe complications that are frequently associated with the enterovirus of serotype EV71. Therefore, the development of a broadly effective and safe anti-enterovirus agent is an existential necessity. In this study, human single-chain antibodies (HuscFvs) specific to the EV71-internal capsid protein (VP4) were generated using phage display technology. VP4 specific-HuscFvs were linked to cell penetrating peptides to make them cell penetrable HuscFvs (transbodies), and readily accessible to the intracellular target. The transbodies, as well as the original HuscFvs that were tested, entered the enterovirus-infected cells, bound to intracellular VP4, and inhibited replication of EV71 across subgenotypes A, B, and C, and coxsackieviruses CVA16 and CVA6. The antibodies also enhanced the antiviral response of the virus-infected cells. Computerized simulation, indirect and competitive ELISAs, and experiments on cells infected with EV71 particles to which the VP4 and VP1-N-terminus were surface-exposed (i.e., A-particles that don't require receptor binding for infection) indicated that the VP4 specific-antibodies inhibit virus replication by interfering with the VP4-N-terminus, which is important for membrane pore formation and virus genome release leading to less production of virus proteins, less infectious virions, and restoration of host innate immunity. The antibodies may inhibit polyprotein/intermediate protein processing and cause sterically strained configurations of the capsid pentamers, which impairs virus morphogenesis. These antibodies should be further investigated for application as a safe and broadly effective HFMD therapy.

Copyright © 2020 Phanthong, Densumite, Seesuay, Thanongsaksrikul, Teimoori, Sookrung, Poovorawan, Onvimala, Guntapong, Pattanapanyasat and Chaicumpa.

Keywords: EV71; VP4; cell penetrating antibody (transbody); coxsackieviruses; human single-chain antibodies; plaque assay; real-time RT-PCR

References

  1. J Mol Biol. 1968 Apr 28;33(2):369-78 - PubMed
  2. Clin Dev Immunol. 2012;2012:980250 - PubMed
  3. Expert Rev Vaccines. 2016;15(4):467-82 - PubMed
  4. Biomed Res Int. 2018 May 28;2018:9747549 - PubMed
  5. J Gen Virol. 2016 Dec;97(12):3238-3242 - PubMed
  6. PLoS Pathog. 2015 Jan 23;11(1):e1004613 - PubMed
  7. Clin Exp Vaccine Res. 2017 Jan;6(1):4-14 - PubMed
  8. J Virol. 2011 Nov;85(22):11809-20 - PubMed
  9. J Gen Virol. 2004 Jul;85(Pt 7):1801-1813 - PubMed
  10. PLoS One. 2016 Mar 23;11(3):e0152177 - PubMed
  11. Pediatr Infect Dis J. 2009 Oct;28(10):904-10 - PubMed
  12. World J Gastroenterol. 2011 Sep 28;17(36):4135-42 - PubMed
  13. Biophys J. 2003 Sep;85(3):1725-33 - PubMed
  14. Clin Infect Dis. 1999 Jul;29(1):184-90 - PubMed
  15. Nat Rev Microbiol. 2004 Sep;2(9):695-703 - PubMed
  16. J Proteomics. 2009 Mar 6;72(2):270-82 - PubMed
  17. Arch Virol. 2011 Nov;156(11):2007-13 - PubMed
  18. J Virol. 2015 Dec;89(23):12084-95 - PubMed
  19. Int J Infect Dis. 2010 Dec;14(12):e1076-81 - PubMed
  20. Expert Rev Vaccines. 2016 May;15(5):599-606 - PubMed
  21. Lancet Infect Dis. 2010 Nov;10(11):778-90 - PubMed
  22. J Virol. 2009 Jul;83(14):7040-8 - PubMed
  23. Trends Pharmacol Sci. 2004 Jun;25(6):306-10 - PubMed
  24. Virol J. 2009 Sep 15;6:141 - PubMed
  25. J Infect Dis. 2008 Mar 15;197(6):854-7 - PubMed
  26. J Immunol. 2005 Sep 1;175(5):2851-8 - PubMed
  27. Nature. 2001 Oct 18;413(6857):732-8 - PubMed
  28. J Virol. 1994 Jun;68(6):3965-70 - PubMed
  29. Emerg Infect Dis. 2003 Mar;9(3):291-3 - PubMed
  30. Emerg Infect Dis. 2018 Jul;24(7):1386-1387 - PubMed
  31. J Biomed Sci. 2019 Oct 18;26(1):75 - PubMed
  32. J Infect Dis. 2011 Jun 15;203(12):1784-90 - PubMed
  33. Sci Rep. 2015 Sep 23;5:14302 - PubMed
  34. J Virol. 1992 Dec;66(12):6849-57 - PubMed
  35. J Virol. 2015 Apr;89(8):4527-38 - PubMed
  36. J Virol. 1999 Jul;73(7):5249-54 - PubMed
  37. Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2134-9 - PubMed
  38. J Gen Virol. 1991 Oct;72 ( Pt 10):2541-4 - PubMed
  39. Virol J. 2011 Mar 08;8:106 - PubMed
  40. Biochem J. 2015 Oct 15;471(2):221-30 - PubMed
  41. Virology. 1991 Apr;181(2):500-11 - PubMed
  42. Viruses. 2015 Dec 08;7(12):6441-57 - PubMed
  43. J Virol. 2014 Sep 1;88(17):9830-41 - PubMed
  44. Nature. 1987 Jun 11-17;327(6122):482-6 - PubMed
  45. Sci Rep. 2017 May 2;7(1):1296 - PubMed
  46. PLoS Pathog. 2018 Aug 6;14(8):e1007203 - PubMed
  47. J Biomed Sci. 2020 Jan 10;27(1):23 - PubMed
  48. Mol Ther. 2007 Nov;15(11):1931-8 - PubMed
  49. Sci Rep. 2015 Dec 18;5:18541 - PubMed
  50. Front Microbiol. 2017 Nov 28;8:2249 - PubMed
  51. PLoS One. 2012;7(1):e29751 - PubMed
  52. Science. 1985 Jun 14;228(4705):1315-7 - PubMed
  53. PLoS Pathog. 2017 Sep 22;13(9):e1006625 - PubMed
  54. N Engl J Med. 1994 Dec 15;331(24):1649-50 - PubMed
  55. J Virol. 2012 Apr;86(7):3767-76 - PubMed
  56. J Biol Chem. 2017 Jun 16;292(24):10262-10274 - PubMed
  57. Front Immunol. 2016 Aug 26;7:318 - PubMed
  58. J Virol. 2014 May;88(10):5816-33 - PubMed
  59. MAbs. 2009 Mar-Apr;1(2):104-11 - PubMed
  60. Br J Pharmacol. 2009 May;157(2):220-33 - PubMed
  61. Virol Sin. 2012 Aug;27(4):221-7 - PubMed
  62. Nat Immunol. 2004 Jul;5(7):730-7 - PubMed
  63. PLoS Pathog. 2013 Mar;9(3):e1003231 - PubMed
  64. PLoS Pathog. 2014 Aug 07;10(8):e1004294 - PubMed
  65. PLoS One. 2019 Nov 27;14(11):e0225569 - PubMed
  66. J Biol Chem. 1994 Apr 8;269(14):10444-50 - PubMed
  67. Immunology. 2013 Mar;138(3):190-7 - PubMed
  68. PLoS Negl Trop Dis. 2014 May 29;8(5):e2895 - PubMed
  69. J Virol. 2019 May 1;93(10): - PubMed
  70. J Infect Dis. 2002 Oct 15;186(8):1161-4 - PubMed
  71. J Virol. 2004 Apr;78(7):3663-74 - PubMed
  72. Vaccine. 2011 Jun 10;29(26):4362-72 - PubMed
  73. Hum Vaccin Immunother. 2014;10(11):3270-85 - PubMed
  74. J Immunol. 2011 Sep 1;187(5):2202-12 - PubMed
  75. Emerg Infect Dis. 2013 Apr;19(4):641-3 - PubMed
  76. Expert Rev Vaccines. 2016;15(1):129-37 - PubMed
  77. J Virol. 2015 Feb;89(3):1900-8 - PubMed
  78. J Virol. 2015 Jul;89(14):7028-37 - PubMed
  79. Nat Med. 2009 Jul;15(7):794-7 - PubMed
  80. Antivir Ther. 2011;16(1):51-8 - PubMed
  81. J Virol. 1990 May;64(5):2433-6 - PubMed
  82. J Virol. 2010 Aug;84(16):8051-61 - PubMed
  83. PLoS Pathog. 2014 Apr 10;10(4):e1004052 - PubMed
  84. BMC Microbiol. 2013 Dec 10;13:287 - PubMed
  85. Antiviral Res. 2016 Sep;133:191-5 - PubMed
  86. J Virol. 2013 Feb;87(3):1690-8 - PubMed
  87. J Virol. 2013 Jan;87(1):611-20 - PubMed
  88. Front Microbiol. 2016 Mar 30;7:391 - PubMed
  89. J Virol. 2003 May;77(9):5266-74 - PubMed
  90. J Control Release. 2010 Oct 15;147(2):171-9 - PubMed
  91. Case Rep Dermatol. 2013 Aug 07;5(2):203-9 - PubMed
  92. Clin Infect Dis. 2010 Jan 1;50(1):125-6 - PubMed
  93. PLoS One. 2013 May 01;8(5):e63431 - PubMed
  94. Microb Pathog. 2019 Sep;134:103568 - PubMed
  95. World J Gastroenterol. 2010 Jan 14;16(2):201-9 - PubMed
  96. Nat Immunol. 2006 Feb;7(2):131-7 - PubMed
  97. J Virol. 2019 Mar 5;93(6): - PubMed
  98. J Virol. 1996 Oct;70(10):7125-31 - PubMed
  99. Antiviral Res. 2013 Oct;100(1):226-37 - PubMed
  100. J Virol. 2011 Sep;85(17):8811-8 - PubMed
  101. Nat Med. 2009 Jul;15(7):798-801 - PubMed
  102. Ther Adv Vaccines Immunother. 2019 Nov 21;7:2515135519888998 - PubMed
  103. Annu Rev Immunol. 2014;32:513-45 - PubMed
  104. J Virol. 2010 Apr;84(7):3339-50 - PubMed
  105. PLoS Pathog. 2013 Mar;9(3):e1003240 - PubMed
  106. Front Microbiol. 2018 Feb 21;9:286 - PubMed
  107. Virol J. 2010 May 26;7:106 - PubMed
  108. J Biol Chem. 2012 Feb 24;287(9):6406-20 - PubMed

Publication Types